ERBB2 and ovarian carcinoma: However, unlike breast cancer, it is controversial to what extent HER-2 amplification and protein overexpression correlate with prognosis (Fan et al, 1994; Fajac et al, 1995), although it has been reported that HER-2 expression is more frequent in ovarian carcinomas relapsing after chemotherapy (Meden et al, 1998).